Identification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy
A plasma metabolite-based risk score derived from six biomarkers independently predicts survival in advanced GC treated with PD-1-based immunotherapy and offers a practical tool for individualized prognosis.
Authors
- Shenghong Wei
- Bijuan Chen (ORCID: https://orcid.org/0000-0002-9817-7220)
- Hanchen Zheng
- X. Wang
- Sha Huang (ORCID: https://orcid.org/0000-0003-2589-5181)
- Qiaoting Hu
- Zhouwei Zhan
- Jiami Yu
- Muqun He
- Zengqing Guo
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3389/fimmu.2026.1714472
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00